BLUEBERRIES MEDICAL CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.015 CAD | -.--% |
|
-.--% | -25.00% |
| 26/04 | Blueberries Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Blueberries Medical Corp. announced that it has received CAD 1.987876 million in funding | CI |
| Sales 2022 | 0.24 0.32 19.65 | Sales 2023 | 0.29 0.4 24.06 | Capitalization | 7.98M 10.99M 666M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.38M -83.46M | Net income 2023 | -1M -1.38M -83.46M | EV / Sales 2022 | 1,82,19,899 x |
| Net cash position 2022 | 76.33K 105K 6.37M | Net cash position 2023 | 805K 1.11M 67.22M | EV / Sales 2023 | 2,48,90,204 x |
| P/E ratio 2022 |
-2.3
x | P/E ratio 2023 |
-2.68
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.21% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -25.00% | ||
| 1 month | -25.00% | ||
| 3 months | -40.00% | ||
| Current year | -25.00% |
1 week
0.02
0.03
1 month
0.000.03
Current year
0.000.04
1 year
0.000.04
3 years
0.000.13
5 years
0.000.74
10 years
0.000.88
| Managers | Title | Age | Since |
|---|---|---|---|
Facundo Garretón
CEO | Chief Executive Officer | - | 20/21/20 |
| Director of Finance/CFO | - | 01/21/01 | |
| Corporate Officer/Principal | - | 16/21/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Facundo Garretón
CEO | Chief Executive Officer | - | 20/21/20 |
| Director/Board Member | - | - | |
| Director/Board Member | 49 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 0.015 | -.--% | 78,666 |
| 26/24/26 | 0.015 | -.--% | 340,333 |
| 25/24/25 | 0.015 | -.--% | 535,133 |
Delayed Quote Canadian Securities Exchange, April 01, 2024 at 01:21 am IST
More quotes
Blueberries Medical Corp. is a Canada-based company, which is a licensed producer of psychoactive and non-psychoactive cannabis by-products in Colombia. The Company is engaged in the growth, cultivation, and development of medicinal cannabis and related products with operations in Colombia. The Company is focused on processing and supplying medicinal-grade Cannabis oil extracts, medical flowers, and related products. It is developing and commercializing a range of cannabis-derived ingredients, including high and low tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids. The Companyâs subsidiaries include Blueberries Research Corporation (BRC), Blueberries SAS (BBSAS), Centro De Desarrollo e Investigacion (CDIBBSAS), BBV Labs Inc. (BBV Labs.) and SATIN S.A.S. (SATIN). Blueberries SAS is a licensed producer and distributor of medicinal Cannabis and Cannabis-derived products in Colombia.
Sector
Drug Retailers
Calendar
27/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.00% | 4.35M | |
| +41.56% | 3.65B | |
| +15.65% | 2.15B | |
| +118.82% | 741M | |
| +34.09% | 625M | |
| +48.36% | 182M | |
| +8.64% | 104M | |
| +57.30% | 58.4M |
- Stock Market
- Equities
- BBM Stock
